Commitments and Contingencies (Details)							1 Months Ended
	Apr. 14, 2021 shares	Apr. 13, 2020 Number	Feb. 11, 2020 USD ($)	Jun. 21, 2019 USD ($)	Jan. 01, 2019 USD ($)	Sep. 12, 2018 USD ($)	Apr. 30, 2021	Jan. 31, 2020 USD ($)	Jul. 21, 2021 USD ($)	Jun. 15, 2020 USD ($)
Other Commitments [Line Items]
Damages value			$ 2,861,401.66		$ 2,100,000	$ 761,401.66
Recovery of damages									$ 67,125.83
Description of commitments							provide for an annual base salary of $400,000 provide for a performance bonus structure for a bonus of up to 50% of base salary upon the Company’s achievement of $2,000,000 EBITDA and additional performance bonus payments for the achievement of EBITDA in excess of $2,000,000 based on a percentage of the incremental increase in EBITDA (ranging from 10% of the incremental increase in EBITDA if the Company achieves over $2,000,000 and up to $7,000,000 in EBITDA, 8% of the incremental increase in EBITDA if the Company achieves over $7,000,000 and up to $12,000,000 in EBITDA and 3% of the incremental increase in EBITDA over $12,000,000), provide for a profits-based additional bonus of up to $250,000 in certain limited circumstances, and provide for one (1) year severance, plus a pro-rated amount of any unpaid bonus earned by him during the year as verified by the Company’s principal financial officer, if Mr. Galvin is terminated without cause. At the Company’s option, up to fifty (50%) percent of the EBITDA performance bonuses may be paid in restricted stock units if then available for grant under the Company’s Stock Incentive Plan.All other terms of the employment agreement remain in full force and effect.
Unpaid wages				$ 30,428.71				$ 372,638
severance								$ 300,000		$ 300,000
Number of units received | shares	2,000,000
Osang Healthcare Company Ltd [Member]
Other Commitments [Line Items]
Description of commitments	The Company has asserted that Osang materially breached a certain Managed Supply Agreement (“MSA”) entered into between the parties on October 12, 2020, pursuant to which the Company received on consignment two million (2,000,000) units of Osang’s “Genefinder Plus RealAmp Covid-19 PCR Test” (the “Covid-19 Test”) for domestic and international distribution. The Company has also asserted that Osang breached the covenant of good faith and fair dealing, fraudulently induced it to enter into the MSA, and violated §349 of the New York General Business Law’s prohibition of deceptive business practices.
HOLA Defendants
Other Commitments [Line Items]
Loss Contingency, New Claims Filed, Number | Number		7